Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model

Radiation Oncology Investigations

Volumn 5, Issue 2, 1997, Pages 62-71

  Joschko, Marion A ^a   Webster, Lorraine K ^a   Groves, Janice ^a   Yuen, Kally ^a   Palatsides, Manuela ^a   Ball, David L ^a   Millward, Michael J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Gemcitabine; Radiosensitizer; Squamous carcinoma; Xenograft

Indexed keywords

CYTARABINE; CYTIDINE DERIVATIVE; GEMCITABINE; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; PRIORITY JOURNAL; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIATION-SENSITIZING AGENTS; RIBONUCLEOTIDE REDUCTASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030751501     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1997)5:2<62::AID-ROI4>3.0.CO;2-H     Document Type: Article

References (28)

1. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2-deoxycytidine). Cancer Res 50:4417-4422, 1990.
2. Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031, 1988.
3. Heinemann V, Xu Y, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res 52:533-539, 1992.
4. Ruiz van Haperen VWT, Veerman G, Vermoken JB, Peters GJ: 2′,2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 46:762-766, 1993.
5. Braakhuis BJM, van Dongen GAMS, Vermorken JB, Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51:211-214, 1991.
6. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerman G, Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 22(Suppl 11):42-62, 1995.
7. Kaye SB: Gemcitabine: Current status of phase I and phase II trials. J Clin Oncol 12:1527-1531, 1994.
8. Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Wallings J, Harris AL: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995.
9. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H, Kaye SB: A phase II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:543-547, 1994.
10. Lund B, Ryberg M, Meidahl-Petersen P, Anderson H, Thatcher N, Dombernowsky P: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 5:852-853, 1994.
11. Byfield JE: 5-Fluorouracil radiation sensitization. A brief review. Invest New Drugs 7:111-116, 1989.
12. Rockwell S, Grindey GB: Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res 4:151-155, 1992.
13. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS: Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223, 1994.
14. Meyn R, Stephens L, Hunter N, Milas L: Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas. Int J Cancer 60:725-729, 1995.
15. Milas L, Hunter N, Kurdoglu B, Mason K, Meyn R, Stephens L, Peters L: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian adenocarcinomas treated with taxol (paclitaxel). Cancer Chemother Pharmacol 35:297-303, 1995.
16. Stephens L, Ang K, Schultheiss T, Milas L, Meyn R: Apoptosis in irradiated murine tumors. Radiat Res 127: 308-316, 1991.
17. Bouffard DY, Momparler RL: Comparison of the induction of apoptosis in human Ieukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leukemia Res 19:849-856, 1995.
18. Huang P, Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol 22(Suppl 11):19-25, 1995.
19. Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ: Enhancement of tumor radioresponse by taxol. Cancer Res 54:3506-3510, 1994.
20. Wheeler JA, Stephens LC, Milas L, Hunter NR, Willingham VI, Meyn RE: Cisplatin-induced enhancement of radioresponse in a murine mammary carcinoma: Test of a role for apoptosis. Radiat Oncol Invest 3:225-231, 1996.
21. Joschko MA, Webster LK, Groves J, Yuen K, Bishop JF, Millward MJ, Ball DL: Schedule-dependent radiation enhancement by paclitaxel with accelerated fractionated radiation in a human squamous carcinoma xenograft. Radiat Oncol Invest 4:268-274, 1996.
22. Gregoire V, Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN: Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res 54:468-474, 1994.
23. Kallman RF, Rapacchietta D, Zaghloul MS: Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems. Int J Radiat Oncol Biol Phys 20:227-232, 1991.
24. Dixon WJ, Brown MB, Engelman L, Jenrich RI: BMDP Statistical Software Manual. Berkeley: University of California Press, 1988.
25. Boven E, Schipper H, Erkelens CAM, Hatty SA, Pinedo HM: The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 68:52-56, 1993.
26. Veerman G, Ruiz van Haperen VWT, Vermorken JB, Noordhuis P, Braakhuis BJM, Pinedo HM, Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 38:335-342, 1996.
27. Lelieveld P, Smink T, van Putten L: Experimental studies on the combination of radiation and chemotherapy. Int J Radiat Oncol Biol Phys 4:37-41, 1978.
28. Kim JH, Alfieri AA, Kim SH, Fuks Z: The potentiation of radiation response on murine tumor by fludarabine phosphate. Cancer Lett 31:69-76, 1986.